Provided is the use of a composition comprising nanoparticles comprising paclitaxel and an albumin in the manufacture of a medicament for treating non-small-cell lung cancer (NSCLC) in an individual in conjunction with b) an effective amount of a platinum-based agent, preferably carboplatin, wherein treatment is based upon the individual having one or more characteristics of (i) having diabetes, and (ii) having four or more metastatic sites.
